Shares of Johnson & Johnson (NYSE:JNJ) have earned a consensus rating of “Buy” from the thirteen research firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $147.30.
JNJ has been the subject of several recent analyst reports. Citigroup raised their target price on shares of Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a report on Monday, February 25th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price target for the company in a report on Wednesday, March 27th. Raymond James raised their price target on shares of Johnson & Johnson from $145.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 17th. Finally, Credit Suisse Group raised their price target on shares of Johnson & Johnson from $151.00 to $152.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th.
In related news, Director Marillyn A. Hewson purchased 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The stock was acquired at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at approximately $419,040. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.23% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Meeder Asset Management Inc. raised its position in shares of Johnson & Johnson by 29.1% in the fourth quarter. Meeder Asset Management Inc. now owns 98,256 shares of the company’s stock valued at $12,679,000 after purchasing an additional 22,157 shares during the period. Vanguard Group Inc raised its position in shares of Johnson & Johnson by 1.5% in the third quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after purchasing an additional 3,235,861 shares during the period. Andesa Financial Management Inc. raised its position in shares of Johnson & Johnson by 72.3% in the third quarter. Andesa Financial Management Inc. now owns 9,977 shares of the company’s stock valued at $1,378,000 after purchasing an additional 4,187 shares during the period. Freestone Capital Holdings LLC raised its position in shares of Johnson & Johnson by 8.3% in the fourth quarter. Freestone Capital Holdings LLC now owns 25,526 shares of the company’s stock valued at $3,294,000 after purchasing an additional 1,954 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $213,000. Hedge funds and other institutional investors own 66.90% of the company’s stock.
Shares of JNJ traded up $1.90 during midday trading on Wednesday, hitting $141.68. The stock had a trading volume of 8,873,955 shares, compared to its average volume of 6,909,619. Johnson & Johnson has a fifty-two week low of $120.11 and a fifty-two week high of $148.99. The stock has a market cap of $367.86 billion, a price-to-earnings ratio of 17.32, a PEG ratio of 2.39 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping the consensus estimate of $2.03 by $0.07. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The company had revenue of $20.02 billion during the quarter, compared to analysts’ expectations of $19.55 billion. During the same period last year, the company posted $2.06 earnings per share. The business’s revenue for the quarter was up .1% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th were issued a dividend of $0.95 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 annualized dividend and a dividend yield of 2.68%. The ex-dividend date of this dividend was Friday, May 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Current Ratio
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.